$CAH

Cardinal Health CEO discussed the company’s M&A approach, saying it is investing to expand specialty services, a fragmented market, through “bolt-on” acquisitions and MSOs that add scale and ancillary offerings. He also said drug pricing changes set by manufacturers have limited direct impact on Cardinal’s profitability, with volume driving results.

Cardinal Health (CAH) reported stronger Q4 and full-year results, with quarterly sales of US$63,672 million and quarterly net income of US$398 million, and expanded its revolving credit capacity to US$4.00 billion. The company authorized a new US$5.00 billion share repurchase program and declared a US$0.5158 quarterly dividend, while continuing product recall activity.

Cardinal Health (CAH) says Q2 CY2026 performance will be driven by specialty pharma and biopharma demand, margin initiatives, and ramp-up of recent acquisitions. It expects double-digit growth in specialty and biopharma solutions, while cost optimization in medical products targets input-cost pressure. Management cites tariff effects as a partial offset and notes regulatory and geopolitical risks. CAH trades at $241.71.

Investing.com reports the S&P 500 closed at a record 7,799 after July CPI and PPI came in cooler than expected, reducing September rate-hike odds from 55% to 35%. The article cites Fed uncertainty, Q2 earnings beats across the S&P 500, and geopolitical risks around the Strait of Hormuz affecting oil and gas.

Markets were mostly higher as investors weighed President Trump’s harder stance toward Iran, reducing expectations for a near-term deal to reopen the Strait of Hormuz. Oil, Treasury yields, and European bonds moved accordingly. US movers included ASML, KLA, Rapid7 (raised EPS forecast), Jabil (UBS upgrade), and Riot Platforms (cloud deal).

US President Trump signaled he may allow economic pressure on Iran to build instead of adding military strikes, amid renewed Middle East risks including a missile attack on a UAE tanker and a Houthi claim on Saudi Arabia’s Jazan refinery. Markets are mixed, with rate-hike odds for the FOMC and ECB and bond yields moving lower. Several US stocks rose on earnings or upgrades, including CAH, RPD, and RIOT; others fell, including ONON and APP.

Insider Monkey highlights nine companies that beat Q2 EPS expectations among 350+ firms reporting by Aug. 11. Reported EPS surprises include RideNow Group (RDNW) $0.16 vs $0.13, Anterix (ATEX) $0.01 vs -$0.17, Super Micro Computer (SMCI) $1.70 vs $0.96, and Fennec Pharmaceuticals (FENC) $0.05 vs $0.01. The rest of the piece shifts to AI themes and promotional content.

Jim Cramer’s “top 10 things to watch” covers July CPI (headline 3.4% YoY, core 2.5%), with 2-year Treasury yields moving lower. He also cites stock moves and analyst actions: CoreWeave up ~19% on results, Super Micro target boosts to $39, Aramark target to $71, Cardinal Health target raised, Intuitive Surgical upgraded, Palo Alto Networks target to $415, Novo Nordisk downgraded, and On Holding removed after guidance cuts.

U.S. indexes drifted lower as crude oil and interest rates were mostly flat, with investors awaiting the July CPI report. FactSet data for 88% of S&P 500 firms showed 86% positive earnings surprises and 76% positive revenue surprises. Nasdaq fell 0.6% to 26,445, S&P 500 0.3% to 7,728, Dow 0.3% to 53,791. CoreWeave (CRWV) and Super Micro (SMCI) report after the close; Nvidia (NVDA) and Intel (INTC) were also discussed.

Cardinal Health (CAH) reported fiscal 2026 Q4 results for the three months ended June 30. Revenue rose about 6% to $63.67B, below LSEG’s $65.03B estimate. Adjusted EPS was $2.60 vs $2.42 consensus, excluding a 31-cent tariff-refund benefit. The firm raised its price target to $265 from $245 and kept a hold-equivalent 2 rating.